General

Cell Line

hPSCreg name LEIi004-A
Cite as:
LEIi004-A (RRID:CVCL_VE61)
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
WTSIi691-A
(HPSI1116i-eiyy_1)
Donor diseases:
Retinitis pigmentosa
WTSIi693-A
(HPSI1116i-zies_2)
Donor diseases:
Retinitis pigmentosa
WTSIi698-A
(HPSI1116i-aimh_5)
Donor diseases:
Retinitis pigmentosa
WTSIi713-A
(HPSI0816i-xoga_7)
Donor diseases:
Retinitis pigmentosa
WTSIi693-B
(HPSI1116i-zies_6)
Donor diseases:
Retinitis pigmentosa
WTSIi698-B
(HPSI1116i-aimh_3)
Donor diseases:
Retinitis pigmentosa
WTSIi688-B
(HPSI1116i-wiau_4)
Donor diseases:
Retinitis pigmentosa
WTSIi613-B
(HPSI1116i-rafd_1)
Donor diseases:
Retinitis pigmentosa
WTSIi613-A
(HPSI1116i-rafd_4)
Donor diseases:
Retinitis pigmentosa
LUMCi056-A-1
(LUMC0128iCRB01 heterozygote CRISPR corrected isogenic clone 02, iso02LUMC0128iCRB01)
Donor's gene variants:
CRB1, CRB1
Donor diseases:
Retinitis Pigmentosa
WTSIi713-B
(HPSI0816i-xoga_12)
Donor diseases:
Retinitis pigmentosa
WTSIi688-A
(HPSI1116i-wiau_1)
Donor diseases:
Retinitis pigmentosa
WTSIi694-A
(HPSI0816i-oemk_6)
Donor diseases:
Retinitis pigmentosa
WTSIi463-A
(HPSI0716i-yibs_1)
Donor diseases:
Retinitis pigmentosa
RIi012-A
(RP.1.H.iPSC.2)
Donor diseases:
Retinitis pigmentosa
WTSIi659-B
(HPSI1116i-wakr_6)
Donor diseases:
Retinitis pigmentosa
WTSIi610-A
(HPSI1116i-naum_5)
Donor diseases:
Retinitis pigmentosa
IDVi001-A
(iPS-NR2E3-86)
Donor diseases:
Retinitis pigmentosa
WTSIi659-A
(HPSI1116i-wakr_3)
Donor diseases:
Retinitis pigmentosa
WTSIi463-B
(HPSI0716i-yibs_3)
Donor diseases:
Retinitis pigmentosa
UNEWi001-A
(UNEW001Ai)
Donor's gene variants:
PRPF31
Donor diseases:
Retinitis pigmentosa
UNEWi002-A
(UNEW002Ai, PRPF31 AW)
Donor's gene variants:
PRPF31, PRPF31
Donor diseases:
Retinitis pigmentosa
UNEWi003-A
(PRPF31-HD)
Donor diseases:
Retinitis pigmentosa
ESi077-A
(CABi001-A, PRPF31-MiPS4F3)
Donor's gene variants:
PRPF31, PRPF31
Donor diseases:
Retinitis Pigmentosa
CIRMi525-A
(CW70348)
Donor diseases:
retinitis pigmentosa
FRIMOi002-A
(RP2_FiPS4F2.2)
Donor diseases:
Retinitis Pigmentosa
FRIMOi005-A
(RP3_FiPS4F11)
Donor diseases:
Retinitis Pigmentosa
UNEWi027-A
(F116)
Donor's gene variants:
PRPF31
Donor diseases:
Retinitis pigmentosa
UNEWi004-A
(PRPF31 SH)
Donor's gene variants:
PRPF31
Donor diseases:
Retinitis pigmentosa
UNEWi005-A
(PRPF31 RH)
Donor's gene variants:
PRPF31
Donor diseases:
Retinitis pigmentosa
CIRMi508-A
(CW70323)
Donor diseases:
retinitis pigmentosa
CIRMi519-A
(CW70342)
Donor diseases:
retinitis pigmentosa
MUi038-A
(EYS mutation)
Donor diseases:
retinitis pigmentosa
FRIMOi001-A
(RP1_FiPS4F1.6)
Donor diseases:
Retinitis Pigmentosa
LUMCi055-A
(CRB1 patient 117 compound heterozygous 2983G>T p.(Glu995*) c.1892A>G, p.(Tyr631Cys), LUMC0117iCRB01)
Donor's gene variants:
CRB1, CRB1
Donor diseases:
Retinitis Pigmentosa
CIRMi531-A
(CW70356)
Donor diseases:
retinitis pigmentosa
LUMCi056-A
(CRB1 patient 128 compound heterozygous c.2843G>A p.(Cys948Tyr) and c.3122T>C p.(Met1041Thr), LUMC0128iCRB01)
Donor's gene variants:
CRB1, CRB1
Donor diseases:
Retinitis Pigmentosa
CABi002-A
(OF0176-EYS02-C7, EYS02-MiPS4F7)
Donor diseases:
Retinitis Pigmentosa
CIRMi542-A
(CW70373)
Donor diseases:
retinitis pigmentosa
NUIGi027-A
(RP001C8)
Donor diseases:
Retinitis Pigmentosa
NUIGi028-A
(RP002C12)
Donor diseases:
Retinitis Pigmentosa
NUIGi029-A
(RP003C12)
Donor diseases:
Retinitis Pigmentosa
RIi009-A
(RP2.H.iPSC.3)
Donor diseases:
Retinitis pigmentosa
Last update 22nd May 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Lions Eye Institute (LEI)
Owner Lions Eye Institute (LEI)
Derivation country Australia

External Databases

BioSamples SAMEA104626352
Cellosaurus CVCL_VE61
Wikidata Q54902437

General Information

Publications
* Is the cell line readily obtainable for third parties?
No
Subclones

Donor Information

General Donor Information

Sex female
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Disease associated phenotypes
  • Retinitis Pigmentosa
Family history RCD , CLN3 mutation
Is the medical history available upon request? YES
Is clinical information available? YES

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
Karyotyping method: Molecular karyotyping by SNP array

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA104626353

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Please provide contact information of the holder of the original Donor Information Sheet. fredchen@lei.org.au
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Please provide the contact information fredchen@lei.org.au
Alternatives to consent
Alternative consent approval number
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Yes
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? No
Does consent expressly prevent the derivation of pluripotent stem cells? Yes
Does consent pertain to a specific research project? Yes
Details on restriction to research project The Western Australia Retinal Degeneration (WARD) study
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? Yes
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? No
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? No
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? Yes
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Does consent permit access to medical records of the donor? Yes
Please describe how access is provided: Lions Eye Institute
Does consent permit access to any other source of information about the clinical treatment or health of the donor? Yes
Contact data, institution, or website: Lions Eye Institute
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? UWA Human Research Ethics Committee
Approval number RA/4/1/7916
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? UWA Human Research Ethics Committee
Approval number RA/4/1/7916
Do you have obligations to third parties in regard to the use of the cell line? No
Please describe:
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
Further constraints on use
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? SBI Cat#SC900A-1
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No
Constraints for use or distribution

hIPSC Derivation

General

Source cell type
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative.
Passage number reprogrammed 7

Reprogramming method

Vector type Non-integrating
Vector Episomal
Is reprogramming vector detectable?
Yes
Methods used
PCR
Files and images showing reprogramming vector expressed or silenced

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones Morphology
Derived under xeno-free conditions
Yes
Derived under GMP?
Yes
Available as clinical grade?
Yes

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 20 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
NANOG
Yes
POU5F1 (OCT-4)
Yes
SOX2
Yes
SSEA-4
Yes
Score:
Marker Present Absent
mCpG
OCT4
Self-renewal
Positive
Endoderm
Positive
Mesoderm
Positive
Ectoderm score
Positive
Differentiation Potency

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46+XX
Passage number: 25

Other Genotyping (Cell Line)